Moleculin Legal Wednesday, November 18, 2026 +0.20 Positive

Moleculin Reaffirms Global IP Strategy with South Korean Patent Allowance

Moleculin Biotech announced a patent allowance in South Korea for its Annamycin reconstitution technology. This decision reinforces the company's extensive global intellectual property portfolio as it advances its pivotal MIRACLE trial.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed